Please assess the completion status of the following clinical trial:

Trial Title: A Comparative Trial Focusing on Injections With the Medical Device DV3316 Pen-injector Versus FlexPen®

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 18-74 years (both included) at the time of signing informed consent~* T1DM (Type 1 Diabetes Mellitus) or T2DM (Type 2 Diabetes Mellitus) (as diagnosed clinically) at least 12 months prior to screening~* Daily self-injection(s) with anti-diabetic drug (insulin or Glucagon-Like Peptide-1 (GLP- 1) analogues) in pen-injector or vial/syringe for at least 12 months~* Caucasians~* Body Mass Index (BMI) at least 18.5 kg/m\^2~Exclusion Criteria:~* Known or suspected hypersensitivity to test placebo solution incl. m-cresol and phenol or related products (placebo)~* Female who is pregnant,, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive methods (adequate contraceptive measures as required by local law or practice)~* Known urticaria factitive or abnormal reactions to mechanical trauma~* Haemophilia and any diseases affecting blood coagulation~* Anti-coagulant or inhibitors of platelet aggregation treatment on the day of the visit~* Intake of any pain-relieving or analgesic drugs on the day of the site visit~* Skin diseases and infections of the skin in the injection site areas (abdomen and thighs)~* Lipodystrophia in the injection site areas (abdomen and thighs)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- DV3316 pen-injector (Type: EXPERIMENTAL): None
- FlexPen® (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).